TWF1 Antibody

What is TWF1 and why is it significant in biological research?

TWF1, also known as Twinfilin-1 or Protein A6, is an actin-binding protein with a molecular mass of approximately 38 kDa. It functions primarily by inhibiting actin polymerization through G-actin sequestration and by capping the barbed ends of actin filaments to regulate cellular motility. TWF1 plays a significant role in clathrin-mediated endocytosis and the distribution of endocytic organelles within cells . The protein has gained research importance due to its involvement in cancer progression, particularly in lung adenocarcinoma (LUAD), breast cancer, and pancreatic cancer, making it a potential biomarker and therapeutic target .

What experimental applications are TWF1 antibodies commonly used for?

TWF1 antibodies are extensively used in several experimental applications in molecular and cellular biology research:

• Western Blotting: For detecting TWF1 protein expression levels in tissue or cell lysates, particularly when comparing normal versus diseased states

• Immunocytochemistry/Immunofluorescence (ICC/IF): For visualizing TWF1 localization within cells and its co-localization with other proteins

• Immunohistochemistry: For analyzing TWF1 expression patterns in tissue sections

• Immunoprecipitation: For isolating TWF1 protein complexes to study protein-protein interactions

These methods allow researchers to investigate TWF1's role in normal cellular functions and pathological states, particularly in cancer research contexts .

How should researchers select the appropriate TWF1 antibody for their specific experimental needs?

Selecting the appropriate TWF1 antibody requires careful consideration of several experimental factors:

• Antibody specificity: Verify that the antibody specifically recognizes TWF1 without cross-reactivity to other proteins, particularly other twinfilin family members. Review validation data from manufacturers or published literature .

• Species reactivity: Ensure the antibody reacts with TWF1 from your experimental organism. Common reactivity includes human and mouse TWF1 .

• Application compatibility: Confirm the antibody has been validated for your specific application (WB, IF, IHC, etc.) .

• Clonality consideration:

  • Polyclonal antibodies offer broader epitope recognition but may have batch-to-batch variation

  • Monoclonal antibodies provide consistent specificity but might recognize only a single epitope

• Epitope location: Consider antibodies targeting different regions of TWF1 depending on your research question. C-terminal antibodies are common for full-length protein detection .

Always validate any new antibody in your experimental system before proceeding with critical experiments.

How can researchers effectively use TWF1 antibodies to investigate its role in cancer progression?

Investigating TWF1's role in cancer progression requires sophisticated experimental approaches using validated antibodies:

• Expression correlation studies: Compare TWF1 expression levels between normal and cancerous tissues using quantitative Western blotting with TWF1 antibodies. This approach demonstrated that TWF1 is significantly upregulated in lung adenocarcinoma tissues and correlates with tumor stage, node stage, and clinical classification .

• Immune infiltration analysis: Use TWF1 antibodies in conjunction with immune cell markers to study the correlation between TWF1 expression and immune cell infiltration in tumor microenvironments. Research has shown TWF1 expression is associated with the infiltration of dendritic cells, eosinophils, macrophages, and various T cell populations in LUAD .

• Functional studies using genetic manipulation:

  • Knockdown TWF1 using siRNA or CRISPR-Cas9 and verify knockdown efficiency using TWF1 antibodies

  • Overexpress TWF1 and confirm using antibody detection

  • Assess how these manipulations affect cancer cell proliferation, migration, invasion, and response to therapy

• Mechanistic investigations: Use TWF1 antibodies in co-immunoprecipitation experiments to identify protein interaction partners that might reveal how TWF1 contributes to cancer pathways, such as its relationship with MMP1 protein in LUAD progression .

• Prognostic correlations: Correlate TWF1 expression levels (detected by antibodies) with patient survival data to establish prognostic value, as has been demonstrated for LUAD where TWF1 overexpression is an independent risk factor for poor prognosis .

What are the key considerations for optimizing TWF1 antibody specificity in experimental protocols?

Optimizing TWF1 antibody specificity is crucial for obtaining reliable experimental results:

• Validation through multiple approaches:

  • Use positive and negative control samples (tissues/cells known to express or not express TWF1)

  • Conduct peptide competition assays to confirm binding specificity

  • Compare results from antibodies targeting different epitopes of TWF1

• Epitope accessibility optimization:

  • For fixed samples, test different fixation methods as they can affect epitope availability

  • Optimize antigen retrieval methods for immunohistochemistry applications

  • Consider native versus denatured conditions based on the antibody's recognition properties

• Cross-reactivity assessment:

  • Test antibody reactivity against recombinant TWF1 versus other twinfilin family members

  • Verify specificity using TWF1 knockdown or knockout samples as negative controls

  • Use bioinformatics analysis to predict potential cross-reactive proteins

• Experimental parameter optimization:

  • Titrate antibody concentrations to find the optimal signal-to-noise ratio

  • Adjust blocking conditions to minimize non-specific binding

  • Optimize incubation times and temperatures for maximum specificity

• Application-specific considerations:

  • For Western blotting: Optimize SDS-PAGE conditions and transfer parameters

  • For immunofluorescence: Refine permeabilization and detection methods

These optimization strategies can significantly improve the reliability and specificity of TWF1 antibody-based detection methods .

How does TWF1 expression correlate with immune cell infiltration in cancer research?

TWF1 expression has been shown to correlate with various immune cell populations in the tumor microenvironment, particularly in lung adenocarcinoma:

• Differential immune cell associations:
  Research using the TIMER (Tumor IMmune Estimation Resource) database and TCGA (The Cancer Genome Atlas) data has revealed significant correlations between TWF1 expression and multiple immune cell populations, including:

  Immune Cell Type	Correlation with TWF1 Expression in LUAD
  B cells memory	Significant correlation
  Dendritic cells resting	Significant correlation
  Eosinophils	Significant correlation
  Macrophages M0	Significant correlation
  Macrophages M1	Significant correlation
  Mast cells (activated & resting)	Significant correlation
  Monocytes	Significant correlation
  Neutrophils	Significant correlation
  NK cells (activated & resting)	Significant correlation
  T cells CD4 memory activated	Significant correlation
  T cells gamma delta	Significant correlation
  T cells regulatory (Tregs)	Significant correlation

• Methodological approach for correlation studies:

  • Analyze TWF1 expression using RNA-seq or antibody-based methods

  • Assess immune cell infiltration using computational deconvolution methods or multi-parameter immunohistochemistry

  • Stratify patients into high and low TWF1 expression groups

  • Compare immune cell concentrations between groups using statistical analysis

• Clinical implications:

  • The correlation between TWF1 expression and immune infiltration suggests potential implications for immunotherapy responsiveness

  • Research indicates relationships between TWF1 expression and sensitivity to immune checkpoint blockade (PD1 and CTLA4)

This data suggests TWF1 may influence or be influenced by the tumor immune microenvironment, offering potential avenues for targeted immunotherapy approaches.

What is the optimal protocol for using TWF1 antibodies in Western blotting applications?

The following detailed protocol represents an optimized approach for Western blotting using TWF1 antibodies:

• Sample preparation:

  • Prepare cell or tissue lysates using RIPA buffer supplemented with protease inhibitors

  • Sonicate briefly to shear DNA and reduce sample viscosity

  • Centrifuge at 14,000g for 15 minutes at 4°C to remove debris

  • Quantify protein concentration using BCA or Bradford assay

• SDS-PAGE separation:

  • Use 10% SDS-PAGE gels (TWF1 has a molecular weight of ~38 kDa)

  • Load 20-50 µg of total protein per lane

  • Include positive and negative control samples

  • Run gel at 100V until samples enter resolving gel, then increase to 150V

• Transfer optimization:

  • Use PVDF membrane (0.45 µm pore size) pre-activated with methanol

  • Transfer at 100V for 60-90 minutes or 30V overnight at 4°C

  • Verify transfer efficiency with Ponceau S staining

• Blocking and antibody incubation:

  • Block membrane in 5% non-fat dry milk or BSA in TBST for 1 hour at room temperature

  • Incubate with primary TWF1 antibody (typically 1:1000 dilution) overnight at 4°C

  • Wash 3x for 5 minutes each with TBST

  • Incubate with appropriate HRP-conjugated secondary antibody (typically 1:5000) for 1 hour at room temperature

  • Wash 4x for 5 minutes each with TBST

• Detection and analysis:

  • Apply ECL substrate and detect signal using imaging system

  • Expected TWF1 band should appear at approximately 38 kDa

  • Quantify band intensity using appropriate software, normalizing to loading controls like GAPDH or β-actin

• Troubleshooting common issues:

  • Weak signal: Increase primary antibody concentration or extend incubation time

  • High background: Increase washing steps or use more stringent blocking

  • Multiple bands: Optimize antibody concentration and verify specificity

This protocol has been optimized based on published research utilizing TWF1 antibodies in Western blotting applications.

How can researchers effectively validate TWF1 antibody specificity in their experimental systems?

Validating TWF1 antibody specificity is crucial for ensuring reliable experimental results. A comprehensive validation approach includes:

• Genetic manipulation controls:

  • Compare signal between wild-type cells and TWF1 knockdown/knockout cells

  • Overexpress tagged TWF1 and verify co-localization with antibody signal

  • Use siRNA dose-response experiments to correlate decreasing TWF1 levels with antibody signal reduction

• Peptide competition assay:

  • Pre-incubate TWF1 antibody with excess immunizing peptide

  • Compare signal between blocked and unblocked antibody

  • Significant signal reduction confirms epitope-specific binding

• Multiple antibody comparison:

  • Test multiple antibodies targeting different TWF1 epitopes

  • Concordant results from multiple antibodies increase confidence in specificity

  • Include antibodies from different host species or different clones

• Mass spectrometry validation:

  • Perform immunoprecipitation using the TWF1 antibody

  • Analyze precipitated proteins by mass spectrometry

  • Confirm enrichment of TWF1 peptides in the immunoprecipitated sample

• Cross-species reactivity testing:

  • Test antibody against TWF1 from different species if working with non-human models

  • Verify that observed patterns match known species conservation of TWF1

• Binding mode analysis:

  • Consider computational approaches for binding mode analysis as described in recent antibody specificity research

  • This can help understand cross-reactivity with similar epitopes present in related proteins

These validation approaches provide robust evidence for antibody specificity and should be documented in publications to enhance research reproducibility.

What experimental designs are most effective for studying TWF1's role in cancer progression?

Effective experimental designs for studying TWF1's role in cancer progression should incorporate multiple complementary approaches:

• Expression correlation studies in patient samples:

  • Analyze TWF1 expression across large patient cohorts using tissue microarrays

  • Correlate expression with clinicopathological features (tumor stage, grade, metastasis)

  • Perform survival analysis stratifying patients by TWF1 expression levels

  • Research has shown TWF1 overexpression correlates with poor prognosis in LUAD patients

• In vitro functional studies:

  • Genetic manipulation approaches:

    • siRNA/shRNA knockdown of TWF1

    • CRISPR-Cas9 knockout of TWF1

    • Overexpression of wild-type or mutant TWF1

  • Phenotypic assays:

    • Proliferation assays (MTT, BrdU incorporation)

    • Migration assays (wound healing, transwell)

    • Invasion assays (Matrigel-coated transwell)

    • Clonogenic survival assays

    • 3D organoid culture systems

• Mechanistic investigations:

  • Identify TWF1 interaction partners using co-immunoprecipitation and mass spectrometry

  • Analyze downstream signaling pathways affected by TWF1 modulation

  • Study TWF1's impact on actin cytoskeleton dynamics using live-cell imaging

  • Investigate transcriptomic and proteomic changes associated with TWF1 expression

  • Research has shown TWF1 may influence MMP1 expression in LUAD progression

• In vivo models:

  • Generate transgenic or conditional knockout mouse models to study TWF1's role in cancer initiation and progression

  • Use xenograft models with TWF1-manipulated cancer cells to study tumor growth and metastasis

  • Employ patient-derived xenografts to maintain tumor heterogeneity

• Drug sensitivity studies:

  • Test how TWF1 expression levels influence response to conventional therapies

  • Screen for compounds that specifically target cells with altered TWF1 expression

  • Investigate TWF1's role in drug resistance mechanisms

  • Previous research has shown associations between TWF1 expression and sensitivity to drugs like A-770041, Bleomycin, and BEZ235

• Immune context studies:

  • Analyze how TWF1 expression affects immune cell infiltration and function

  • Investigate potential impacts on immunotherapy response

  • Correlate TWF1 levels with immune checkpoint expression

These multi-faceted experimental approaches provide complementary evidence for TWF1's role in cancer and may identify potential therapeutic strategies targeting TWF1 or its associated pathways.

How is TWF1 being investigated as a prognostic biomarker in cancer research?

TWF1 is emerging as a potential prognostic biomarker in cancer research, with several key investigative approaches:

Current research indicates that TWF1 expression is particularly valuable as a prognostic marker in lung adenocarcinoma, where its overexpression correlates with tumor stage, node stage, clinical classification, and poor survival outcomes .

What are the emerging applications of TWF1 antibodies in immunotherapy research?

TWF1 antibodies are finding emerging applications in immunotherapy research, highlighting the intersection between actin cytoskeleton regulation and immune responses:

• Tumor immune microenvironment characterization:

  • Co-staining of tumor tissues with TWF1 and immune cell markers to understand spatial relationships

  • Analysis of how TWF1 expression in tumor cells correlates with infiltration of specific immune cell populations

  • Research has shown TWF1 expression is associated with the presence of various immune cells, including dendritic cells, macrophages, and T cell populations

• Immunotherapy response prediction:

  • Investigation of TWF1 expression as a potential biomarker for immunotherapy response

  • Correlation studies between TWF1 levels and immune checkpoint expression (PD1, CTLA4)

  • Analysis of how TWF1-mediated changes in tumor cell biology might influence immunotherapy efficacy

• Mechanistic studies in immune cells:

  • Examination of TWF1's role in immune cell function and migration

  • Investigation of how TWF1 might influence immune synapse formation

  • Study of potential roles in antigen presentation and T cell activation

• Therapeutic targeting approaches:

  • Development of strategies to modulate TWF1 expression or function to enhance immunotherapy response

  • Investigation of combination approaches targeting both TWF1-related pathways and immune checkpoints

  • Research on how TWF1 inhibition might alter the tumor immune microenvironment

• Research methodology:

  • Use of multi-parameter immunofluorescence with TWF1 antibodies to characterize complex tumor-immune interactions

  • Single-cell analysis approaches to understand heterogeneity in TWF1 expression and its relationship to immune function

  • Development of in vivo imaging approaches to monitor TWF1 and immune cell dynamics

These emerging applications highlight the potential importance of TWF1 in the interface between cancer cell biology and immunology, suggesting possible new avenues for enhancing immunotherapy approaches .

What are the common challenges and solutions when working with TWF1 antibodies in immunofluorescence applications?

Researchers frequently encounter several challenges when using TWF1 antibodies for immunofluorescence applications. Here are common issues and their solutions:

• High background signal:

  • Challenge: Non-specific binding resulting in diffuse background staining

  • Solutions:

    • Increase blocking time (2-3 hours instead of 1 hour)

    • Use alternative blocking agents (5% BSA, normal serum from secondary antibody host species)

    • Reduce primary antibody concentration

    • Include 0.1-0.3% Triton X-100 in washing buffers

    • Increase washing duration and frequency

• Weak or absent signal:

  • Challenge: Insufficient detection of TWF1

  • Solutions:

    • Optimize fixation method (test paraformaldehyde vs. methanol fixation)

    • Try antigen retrieval methods (citrate buffer, pH 6.0)

    • Increase primary antibody concentration or incubation time

    • Use signal amplification systems (tyramide signal amplification)

    • Ensure appropriate permeabilization for intracellular proteins

• Inconsistent staining patterns:

  • Challenge: Variable results between experiments

  • Solutions:

    • Standardize all protocol steps with precise timing

    • Prepare fresh fixatives and buffers for each experiment

    • Maintain consistent temperature during incubations

    • Use positive control samples with known TWF1 expression

    • Batch process samples for comparative studies

• Autofluorescence interference:

  • Challenge: Tissue or cellular autofluorescence masking specific signal

  • Solutions:

    • Include an autofluorescence quenching step (0.1% Sudan Black B in 70% ethanol)

    • Use confocal microscopy with narrow bandpass filters

    • Consider alternative fluorophores with emission spectra away from autofluorescence

• Specificity concerns:

  • Challenge: Difficulty distinguishing TWF1 from related proteins

  • Solutions:

    • Include TWF1 knockdown/knockout controls

    • Perform peptide competition assays

    • Compare staining patterns with multiple TWF1 antibodies targeting different epitopes

• Subcellular localization accuracy:

  • Challenge: Ensuring accurate visualization of TWF1's subcellular distribution

  • Solutions:

    • Co-stain with markers for subcellular compartments

    • Use super-resolution microscopy techniques

    • Compare native TWF1 staining with tagged TWF1 expression

By systematically addressing these challenges, researchers can optimize TWF1 antibody performance in immunofluorescence applications, leading to more reliable and reproducible results.

How can researchers resolve discrepancies between TWF1 expression data from different antibody-based methods?

Resolving discrepancies between TWF1 expression data obtained from different antibody-based methods requires a systematic troubleshooting approach:

• Methodological differences analysis:

  • Western blot vs. immunohistochemistry: Western blotting detects denatured protein, while IHC detects proteins in their native conformation and cellular context

  • Flow cytometry vs. immunofluorescence: Flow cytometry provides quantitative population data, while IF provides spatial information

  • Solution: Use complementary methods and understand the limitations of each technique

• Antibody characteristic assessment:

  • Epitope differences: Different antibodies recognize distinct regions of TWF1

  • Clonality factors: Monoclonal antibodies target single epitopes while polyclonals recognize multiple sites

  • Solution: Document which epitope each antibody recognizes and test multiple antibodies targeting different regions

• Sample preparation variables:

  • Fixation effects: Overfixation may mask epitopes in IHC/IF but not affect Western blotting

  • Protein extraction efficiency: Different lysis methods may extract TWF1 with varying efficiency

  • Solution: Standardize preparation methods or validate each method independently

• Quantification approach standardization:

  • Relative vs. absolute quantification: Ensure consistent normalization strategies

  • Dynamic range limitations: Each method has different sensitivity and dynamic range

  • Solution: Develop calibration curves with recombinant TWF1 standards

• Validation through orthogonal methods:

  • mRNA correlation: Compare protein detection with RT-qPCR for TWF1 mRNA

  • Mass spectrometry validation: Use antibody-independent methods to verify expression levels

  • Solution: Triangulate results using multiple independent techniques

• Experimental design for reconciliation:

  • Side-by-side comparison: Process the same samples with different methods simultaneously

  • Titration experiments: Perform antibody titrations to ensure optimal working conditions

  • Spike-in controls: Add known quantities of recombinant TWF1 to samples

  • Solution: Design experiments specifically to address discrepancies

By systematically investigating these factors, researchers can identify the sources of discrepancies and develop standardized approaches that yield consistent results across different antibody-based methods.

How is TWF1 being studied in relation to drug resistance mechanisms in cancer?

TWF1's emerging role in drug resistance mechanisms represents an important frontier in cancer research:

• Expression correlation with therapeutic response:

  • Studies have linked TWF1 expression levels with sensitivity to specific anticancer drugs

  • Research indicates associations between TWF1 expression and sensitivity to drugs such as A-770041, Bleomycin, and BEZ235

  • Comparative analysis of TWF1 levels in treatment-responsive versus resistant tumors

• Mechanistic investigations into resistance pathways:

  • Analysis of how TWF1-mediated cytoskeletal changes might influence drug uptake or efflux

  • Study of TWF1's potential roles in regulating pro-survival signaling pathways

  • Investigation of connections between TWF1 and known drug resistance mechanisms like epithelial-mesenchymal transition

• Therapeutic targeting approaches:

  • Testing whether TWF1 inhibition can resensitize resistant cancer cells

  • Development of combination strategies targeting TWF1 alongside primary therapies

  • Evaluation of sequential treatment approaches involving TWF1 modulation

• Experimental models for studying TWF1 in drug resistance:

  • Generation of drug-resistant cell lines with altered TWF1 expression

  • Patient-derived xenograft models from treatment-resistant tumors

  • 3D organoid cultures that better recapitulate in vivo resistance mechanisms

• Clinical research directions:

  • Analysis of TWF1 expression changes during treatment and at relapse

  • Prospective studies evaluating TWF1 as a predictive biomarker for treatment response

  • Investigation of TWF1 in multi-drug resistance phenotypes

• Technological approaches:

  • High-throughput drug screening in models with modified TWF1 expression

  • CRISPR-Cas9 screens to identify synthetic lethal interactions with TWF1 in resistant cells

  • Computational modeling of TWF1's interaction with drug response pathways

This research area represents a promising avenue for understanding and potentially overcoming drug resistance in cancer, with TWF1 antibodies serving as essential tools for these investigations.

What are the latest findings regarding TWF1's role in regulating tumor immune microenvironment?

Recent research has revealed important connections between TWF1 expression and the tumor immune microenvironment:

• Correlation with immune cell infiltration patterns:

  • Comprehensive analysis has shown significant associations between TWF1 expression and multiple immune cell populations in lung adenocarcinoma

  • Notable correlations include relationships with dendritic cells, macrophages (M0 and M1), mast cells, NK cells, and various T cell populations including regulatory T cells

  • These findings suggest TWF1 may influence immune recruitment or retention within tumors

• Impact on immunotherapy response markers:

  • Research indicates connections between TWF1 expression and response to immune checkpoint blockade

  • TWF1 expression has been correlated with PD1 and CTLA4 expression levels

  • Tumor mutation burden (TMB), an important predictor of immunotherapy response, has shown associations with TWF1 expression

• Potential mechanistic connections:

  • Emerging hypotheses suggest TWF1's role in actin cytoskeleton regulation may influence:

    • Immune synapse formation between tumor and immune cells

    • Migration and infiltration capacity of immune cells

    • Antigen presentation mechanisms

    • Tumor cell evasion of immune surveillance

• Experimental approaches being utilized:

  • Single-cell analyses to understand heterogeneity in TWF1 expression and immune interactions

  • Spatial transcriptomics to map TWF1 expression in relation to immune cell locations

  • In vitro co-culture systems modeling tumor-immune interactions with TWF1 manipulation

  • In vivo models examining TWF1's impact on immunotherapy response

• Therapeutic implications under investigation:

  • Potential for TWF1-targeting strategies to enhance immunotherapy efficacy

  • Development of combination approaches targeting both TWF1 and immune checkpoints

  • Exploration of TWF1 as a biomarker for immunotherapy patient selection